Abstract
Memantine hydrochloride (Namenda; Forest/Merz), which acts to protect neurons against toxicity caused by overactivation of N-methyl-D-aspartate receptors, became the first drug to be approved by the US FDA for the treatment of moderate to severe Alzheimer's disease in October 2003, after its approval for the same indication in the European Union in 2002. What influence could this have on its market potential?
Memantine
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Suppression of exaggerated NMDAR activity by memantine treatment ameliorates neurological and behavioral deficits in aminopeptidase P1-deficient mice
Experimental & Molecular Medicine Open Access 03 August 2022
-
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
Neurology and Therapy Open Access 31 July 2022
-
Inhibition of NMDA receptors through a membrane-to-channel path
Nature Communications Open Access 15 July 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mayeux, R. & Sano, M. Treatment of Alzheimer's disease. N. Engl. J. Med. 341, 1670–1679 (1999).
Kemp, J. A. & McKernan, R. M. NMDA receptors as drug targets. Nature Neurosci. 5, 1039–1042 (2002).
Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well-tolerated N-methyl-D-aspartate (NMDA) receptor antagonist — a review of the preclinical data. Neuropharmacology 38, 735–767 (1999).
Gerzon, K. et al. The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N′-adamantylureas. J. Med. Chem. 6, 760–763 (1963).
Bormann, J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166, 591–592 (1989).
Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333–1341 (2003).
FDA Drug Approvals List [online], (cited 28 December 2003), <http://www.fda.gov/cder/foi/label/2003/021487lbl.pdf> (2003).
Alzheimer's Disease (Decision Resources, Waltham, Massachusetts, Pharmacor, 2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Witt, A., Macdonald, N. & Kirkpatrick, P. Memantine hydrochloride. Nat Rev Drug Discov 3, 109–110 (2004). https://doi.org/10.1038/nrd1311
Issue Date:
DOI: https://doi.org/10.1038/nrd1311
This article is cited by
-
Memantine derived compounds as potent in vitro inhibitors of urease: Repurposing of memantine, sonication assisted derivatization and in vitro enzyme inhibition, kinetics and molecular docking studies
Medicinal Chemistry Research (2023)
-
Suppression of exaggerated NMDAR activity by memantine treatment ameliorates neurological and behavioral deficits in aminopeptidase P1-deficient mice
Experimental & Molecular Medicine (2022)
-
Inhibition of NMDA receptors through a membrane-to-channel path
Nature Communications (2022)
-
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
Neurology and Therapy (2022)
-
A human stem cell-derived test system for agents modifying neuronal N-methyl-d-aspartate-type glutamate receptor Ca2+-signalling
Archives of Toxicology (2021)
